InsidersTradesSigma
Track the InfuSystem Holdings, Inc share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, InfuSystem Holdings, Inc has recorded 87 reports. Market capitalisation: €196.1m. The latest transaction was disclosed on 2 March 2026 (Acquisition). Among the most active insiders: Dilorio Richard. Every trade is openly available.
87
Insider Decl.
n/a
Thresholds
€338,679
18 ops.
Buy Volume
€2m
11 ops.
Sell Volume
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,421 of 29,064 companies
67.6
score / 100
Value68
Quality67
FCF yld8.5%
Earn yld3.6%
EV/EBITDA8.2x
ROE14%
Gross mgn56%
Net mgn4.6%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 March 2026
Declarations87 total
2,064 shares@ US$9.1631.4% of flowCommon StockSEC:0001628280-26-013466:0
Canonical exit: 31 May 2026 (T+90)
2,000 shares@ US$5.1830.3% of flowCommon StockSEC:0001628280-25-028163:0
Canonical exit: 26 Aug 2025 (T+90)
5,000 shares@ US$6.09100.0% of flowCommon StockSEC:0001628280-25-026953:0
Canonical exit: 17 Aug 2025 (T+90)
17,727 shares0Common StockSEC:0001628280-25-026955:0
10,000 shares0Common StockSEC:0001628280-25-026952:0
13,636 shares0Common StockSEC:0001628280-25-026949:0
40,909 shares0Common StockSEC:0001628280-25-026950:0
1,165 shares@ US$6.0055.1% of flowCommon StockSEC:0001628280-25-026388:0
Canonical exit: 13 Aug 2025 (T+90)
3,000 shares@ US$5.7644.0% of flowCommon StockSEC:0001628280-25-025637:0
Canonical exit: 12 Aug 2025 (T+90)
25,000 shares@ US$2.604.4% of flowCommon StockSEC:0001628280-25-012164:0
42,241 shares0Common StockSEC:0001628280-24-050270:0
20,000 shares@ US$9.320812.9% of flowCommon StockSEC:0001628280-24-049421:0
20,000 shares0Common StockSEC:0001628280-24-045082:0
12,500 shares0Common StockSEC:0001628280-24-042756:0
4,000 shares@ US$5.89100.0% of flowCommon StockSEC:0001628280-24-041314:0
Canonical exit: 22 Dec 2024 (T+90)
50,000 shares@ US$2.699.1% of flowCommon StockSEC:0001628280-24-030522:0
4,300 shares@ US$6.8571100.0% of flowCommon StockSEC:0001628280-24-025024:0
Canonical exit: 20 Aug 2024 (T+90)
4,000 shares@ US$7.13100.0% of flowCommon StockSEC:0001628280-24-025026:0
Canonical exit: 21 Aug 2024 (T+90)
1,000 shares@ US$6.3875100.0% of flowCommon StockSEC:0001628280-24-024598:0
Canonical exit: 18 Aug 2024 (T+90)
5,000 shares@ US$6.549.2% of flowCommon StockSEC:0001628280-24-024587:0
Canonical exit: 18 Aug 2024 (T+90)
5,052 shares0Common StockSEC:0001628280-24-024603:0
3,886 shares0Common StockSEC:0001628280-24-024607:0
2,850 shares0Common StockSEC:0001628280-24-024592:0
11,659 shares0Common StockSEC:0001628280-24-024605:0
35,000 shares@ US$4.7036.4% of flowCommon StockSEC:0001628280-24-023875:0
25 of 87 declarations
关于 InfuSystem Holdings, Inc
InfuSystem Holdings, Inc.（股票代码：INFU）是一家总部位于美国的医疗保健服务公司，在美国纽约证券交易所美国市场上市，公司总部位于密歇根州罗切斯特山。从股票分析师的角度来看，InfuSystem最好被理解为一家专业的门诊护理基础设施提供商，而非传统的药物或设备制造商。该公司专注于输液泵、相关医疗产品、生物医学服务以及支持分散式护理环境（如肿瘤科诊所、家庭护理、门诊手术中心和其他替代护理场所）的邻近解决方案。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1337013/000162828024015511/infu-20231231.htm?utm_source=openai)) 该业务围绕便携式和大容量输液泵的租赁、销售和支持而发展，并辅以维护、再认证和维修等技术服务。随着时间的推移，InfuSystem通过运营子公司进行扩张，并拓宽了其服务模式，以捕捉设备正常运行时间和临床连续性方面的更多价值链。这在战略上很重要：公司的经济效益不仅与设备投放相关，还与经常性服务、耗材和物流活动相关。这种组合往往比简单的单次设备销售模式更能建立更牢固的客户关系。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1337013/000162828024015511/infu-20231231.htm?utm_source=openai)) 在竞争方面，InfuSystem在北美门诊护理生态系统中占据了利基地位。其业务范围覆盖美国多个地点和加拿大安大略省，支持现场客户服务、某些市场的当日或次日送达能力以及本地生物医学支持模式。在一个可靠性、报销专业知识和快速服务响应至关重要的行业中，这种运营网络是一个重要的差异化因素。该公司还强调了与第三方支付网络的关系以及与门诊肿瘤科诊所的长期合作关系，这两者都可以成为小型竞争对手的进入壁垒。（[infusystem.com](https://infusystem.com/?utm_source=openai)) InfuSystem的核心产品和服务包括输液泵租赁和销售、生物医学服务以及相关耗材和配件。该公司还涉足负压伤口治疗（NPWT），这扩大了其可寻址机会，超越了单纯的输液业务。这种多元化具有相关性，因为它为公司提供了额外的收入增长途径，同时仍处于医疗必需、基本非自由裁量的护理领域。（[annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/I/NYSE_INFU_2023.pdf?utm_source=openai)) 从地理上看，该业务仍集中在美国，在加拿大有较小的业务。这种布局与依赖本地执行而非全球规模的专业医疗保健服务模式相符。公司总部位于密歇根州罗切斯特山，是其北美网络的运营支柱。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1337013/000162828024015511/infu-20231231.htm?utm_source=openai)) 近期发展对投资者很重要。2025年，InfuSystem报告的季度业绩显示调整后EBITDA有所改善，同时继续投资于信息技术系统和服务基础设施。2026年，管理层披露，重组其最大的生物医学服务合同将暂时减少收入，但也重新调整了业务，使其未来收入结构更具可持续性。总的来说，INFU提供了一个专业的、对报销敏感的美国医疗保健服务平台，具有经常性特征、执行风险以及服务扩张和运营纪律带来的潜在上行空间。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1337013/000162828025023417/infu-20250508xexx991earnin.htm?utm_source=openai)
